1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,385 | 1,860 | 04.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.09. | BPC INSTRUMENTS AB: BPC Instruments partners with limu.eco to evaluate additives for biodegradable plastics | 1 | Cision News | ||
| 26.08. | BPC Instruments AB (publ) reports results for H1 and Q2 2026 | 2 | Cision News | ||
| BPC INSTRUMENTS Aktie jetzt für 0€ handeln | |||||
| 10.06. | BPC INSTRUMENTS AB: BPC Instruments receives ISO 9001 certification for quality management | 1 | Cision News | ||
| 26.05. | Bulletin from the Annual General Meeting of BPC Instruments AB (publ) | 1 | Cision News | ||
| 19.05. | BPC Instruments AB: BPC Instruments partners with AURI on anaerobic digestion experimentation in the United States | 842 | PR Newswire | LUND, Sweden, May 19, 2026 /PRNewswire/ -- BPC Instruments AB (publ) ("BPC") has entered a strategic collaboration with the Agricultural Utilization Research Institute ("AURI") to improve... ► Artikel lesen | |
| 06.05. | BPC Instruments AB (publ) reports results for Q1 2026 | 2 | Cision News | ||
| 30.04. | BPC INSTRUMENTS AB: BPC Instruments discloses preliminary figures for the first quarter of 2026 | 1 | Cision News | ||
| 29.04. | BPC Instruments AB (publ) publishes Annual Report for 2025 | 1 | Cision News | ||
| 23.04. | Notice of Annual General Meeting in BPC Instruments AB (publ) | 1 | Cision News | ||
| 26.02. | BPC Instruments AB: BPC Instruments reports results for 2025 | 559 | PR Newswire | LUND, Sweden, Feb. 26, 2026 /PRNewswire/ -- BPC Instruments AB (publ) hereby publishes the year-end report for the year 2025. The year-end report is available as... ► Artikel lesen | |
| 24.02. | BPC Instruments AB: BPC Instruments receives two repeat orders from Denmark within biogas applications | 906 | PR Newswire | LUND, Sweden, Feb. 24, 2026 /PRNewswire/ -- BPC Instruments AB (publ) has received two repeat orders from Denmark within biogas applications with a total value of approximately SEK 1.1 million.... ► Artikel lesen | |
| 19.02. | BPC Instruments AB: BPC Instruments secures order for BPC Blue system from global testing and certification group | 646 | PR Newswire | LUND, Sweden, Feb. 19, 2026 /PRNewswire/ -- BPC Instruments AB (publ) has received an order valued at approximately SEK 0.8 million for BPC's most advanced BPC Blue configuration, including... ► Artikel lesen | |
| 16.12.25 | BPC Instruments AB: BPC Instruments partners with SixRing to provide quality assurance for the EU and UK biomethane markets | 663 | PR Newswire | LUND, Sweden, Dec. 16, 2025 /PRNewswire/ -- BPC Instruments AB (publ) has entered into a collaboration with SixRing, the Canadian technology company behind Stimulose, a new feedstock additive... ► Artikel lesen | |
| 20.11.25 | BPC Instruments AB: BPC Instruments secures new order for several BPC Go units from a international energy group | 647 | PR Newswire | LUND, Sweden, Nov. 20, 2025 /PRNewswire/ -- BPC Instruments AB (publ) has received a new order valued at approximately SEK 0.9 million for several BPC Go units from a major international... ► Artikel lesen | |
| 12.11.25 | BPC Instruments AB: BPC Instruments reports results for the period January - September 2025 | 1.046 | PR Newswire | LUND, Sweden, Nov. 12, 2025 /PRNewswire/ -- BPC Instruments AB (publ) hereby publishes the interim report for the period January 1 - September 30, 2025. The interim report is available... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,405 | +5,80 % | Microsoft, Newron, Pyrum, Qiagen, Börse München - das 4investors.de-Weekend | Was hat Anleger am Wochenende bewegt? Hier sind die 4investors.de-Berichte vom Wochenende mit spannenden Aktien-Stories zu Microsoft, Newron, Pyrum, Qiagen sowie der Börsenpresseschau der Börse München.... ► Artikel lesen | |
| CG ONCOLOGY | 67,38 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 39,640 | 0,00 % | Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days | ||
| TARSUS PHARMACEUTICALS | 73,00 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting | ||
| PRAXIS PRECISION MEDICINES | 295,78 | +0,09 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERA THERAPEUTICS | 30,420 | 0,00 % | Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 | BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,755 | 0,00 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,225 | -0,06 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 10,500 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk | In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized... ► Artikel lesen | |
| MBX BIOSCIENCES | 58,51 | 0,00 % | Guggenheim raises MBX Biosciences price target to $150 on obesity drug potential | ||
| EDGEWISE THERAPEUTICS | 41,400 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 27,790 | 0,00 % | Stifel reiterates Amylyx stock rating on avexitide confidence | ||
| KYMERA THERAPEUTICS | 107,37 | -0,02 % | B.Riley reiterates Kymera Therapeutics stock rating on new trial data | ||
| ADARX PHARMACEUTICALS | 18,250 | 0,00 % | HBM Healthcare Investments AG: HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,125 | +0,12 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen |
BPC INSTRUMENTS AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,623 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BPC INSTRUMENTS AB finden Sie auf Wallstreet Online.